December 22, 2003 - 6:59 p.m.
Gilead Sciences Announces Completion of Redemption of 5% Convertible Subordinated Notes
Printer Friendly Version 
December 22, 2003 - 6:59 p.m.
Gilead Sciences Files $500 Million Shelf Registration Statement
Printer Friendly Version 
December 22, 2003 - 6:57 p.m.
Gilead Sciences Files $500 Million Shelf Registration Statement
Printer Friendly Version 
November 25, 2003 - 4:32 p.m.
Gilead Announces Preliminary Results from 48-Week Phase III Study of Emtricitabine in Patients with Chronic Hepatitis B
Printer Friendly Version 
November 20, 2003 - 4:32 p.m.
Gilead Sciences Calls for Redemption of Convertible Subordinated Notes
Printer Friendly Version 
November 17, 2003 - 7:19 p.m.
Cauley Geller Announces Class Action Lawsuit Against Gilead Sciences, Inc. On Behalf of Investors
Printer Friendly Version 
November 17, 2003 - 6:31 p.m.
Shareholder Class Action Filed Against Gilead Sciences, Inc. by the Law Firm of Schiffrin & Barroway, LLP
Printer Friendly Version 
November 13, 2003 - 4:59 p.m.
Milberg Weiss Announces the Filing of a Class Action Suit against Gilead Sciences, Inc. on Behalf of Investors
Printer Friendly Version 
November 10, 2003 - 8:37 a.m.
Gilead Sciences to Present at Credit Suisse First Boston 2003 Healthcare Conference; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
November 10, 2003 - 8:35 a.m.
Gilead Sciences to Present at Credit Suisse First Boston 2003 Healthcare Conference
Printer Friendly Version 
October 30, 2003 - 8:10 a.m.
Gilead Sciences Amends Stockholder Rights Plan
Printer Friendly Version 
October 28, 2003 - 4:06 p.m.
Gilead Sciences Announces Third Quarter 2003 Financial Results
Printer Friendly Version 
October 28, 2003 - 4:03 p.m.
Gilead Sciences Announces Third Quarter 2003 Financial Results
Printer Friendly Version 
October 28, 2003 - 4:03 p.m.
Gilead Sciences' HIV Drug Emtriva Approved for Marketing in European Union
Printer Friendly Version 
October 28, 2003 - 4:02 p.m.
Gilead Sciences' HIV Drug Emtriva Approved for Marketing in European Union
Printer Friendly Version 
October 28, 2003 - 8:38 a.m.
New Data Highlight Safety and Tolerability Profile of Gilead's Viread for Periods up to Four Years; Data Presented at European AIDS Conference in Warsaw
Printer Friendly Version 
October 28, 2003 - 8:17 a.m.
Gilead Announces 144-Week Data of Hepsera in Patients Co-Infected With HIV And Lamivudine-Resistant HBV
Printer Friendly Version 
October 21, 2003 - 6:16 p.m.
Gilead Sciences to Release Third Quarter Financial Results on Tuesday, October 28, 2003; Conference Call and Webcast to Follow
Printer Friendly Version 
October 14, 2003 - 9:31 a.m.
Mark Perry Joins Nuvelo Board of Directors
Printer Friendly Version 
October 07, 2003 - 8:04 a.m.
IntraBiotics Names Mark L. Perry to Its Board of Directors
Printer Friendly Version 
September 22, 2003 - 4:48 p.m.
Gilead Sciences to Present Corporate Update at the UBS Global Life Sciences Conference on Tuesday, September 23, 2003
Printer Friendly Version 
September 15, 2003 - 8:39 a.m.
Gilead Purchases Foster City Campus
Printer Friendly Version 
August 14, 2003 - 8:35 a.m.
Gilead Signs Agreement to Acquire Foster City Campus
Printer Friendly Version 
August 11, 2003 - 5:03 p.m.
Gilead Initiates Study 934, a 48-Week Clinical Trial Evaluating Viread and Emtriva versus Combivir
Printer Friendly Version 
August 04, 2003 - 8:33 a.m.
Gilead and Chiron Corporation Sign Non-Exclusive HCV Licensing Agreement; Gilead to Initiate Research Programs in Hepatitis C
Printer Friendly Version 
July 31, 2003 - 4:03 p.m.
Gilead Sciences Announces Second Quarter 2003 Financial Results
Printer Friendly Version 
July 31, 2003 - 8:08 a.m.
Gilead and Japan Tobacco Sign Licensing Agreement for Commercialization of Gilead's HIV Products in Japan
Printer Friendly Version 
July 25, 2003 - 8:06 a.m.
Gilead Sciences to Release Second Quarter Financial Results on Thursday, July 31, 2003; Conference Call and Webcast to Follow
Printer Friendly Version 
July 24, 2003 - 4:18 p.m.
European CPMP Gives Positive Opinion on Emtriva, Gilead's New Once-Daily Treatment for HIV
Printer Friendly Version 
July 14, 2003 - 8:35 a.m.
Phase III Trial of Emtriva, New Once-Daily Capsule for HIV, Shows Continued Response Through 60 Weeks
Printer Friendly Version 
July 14, 2003 - 8:26 a.m.
Gilead Sciences Expects Second Quarter 2003 Financial Results Will Exceed Expectations; Increase Driven Primarily by Higher Viread Revenues
Printer Friendly Version 
July 11, 2003 - 8:33 a.m.
Gilead Sciences Announces Selling Securityholder Registration Statement Declared Effective by SEC
Printer Friendly Version 
July 02, 2003 - 1:01 p.m.
U.S. FDA Approves Gilead Sciences' Emtriva, a One-Capsule, Once-Daily Medication for the Treatment of HIV
Printer Friendly Version 
June 24, 2003 - 8:14 a.m.
Gilead and Bukwang End Licensing Agreement for Clevudine, Investigational Agent for Chronic Hepatitis B
Printer Friendly Version 
June 13, 2003 - 8:33 a.m.
96-Week Data from Gilead's Study 903 Show Low Rate of Virologic Failure among Patients Taking Viread
Printer Friendly Version 
June 09, 2003 - 8:36 a.m.
Gilead Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Healthcare Conference; Webcast Available through Gilead Corporate Website
Printer Friendly Version 
May 27, 2003 - 8:14 a.m.
European Commission Expands the Indication of Viread, Gilead's Once-Daily Treatment for HIV, to Include Treatment-Naive Patients
Printer Friendly Version 
May 16, 2003 - 8:32 a.m.
Gilead Launches Web Site for Hepsera, Its Chronic Hepatitis B Drug
Printer Friendly Version 
April 23, 2003 - 4:03 p.m.
Gilead Sciences Announces First Quarter 2003 Financial Results; Record Viread Sales of $107 Million; Product Sales of $156 Million, Up 121 Percent over First Quarter 2002
Printer Friendly Version 
April 18, 2003 - 8:03 a.m.
Gilead Sciences to Release First Quarter Financial Results on Wednesday, April 23, 2003; Conference Call and Webcast to Follow
Printer Friendly Version 
April 09, 2003 - 4:31 p.m.
96-Week Data Show Hepsera Reduces Liver Damage and Improves Liver Function in More Than 70 Percent of Patients with Hepatitis B ``E'' Antigen-Negative Disease
Printer Friendly Version 
April 04, 2003 - 6:03 a.m.
Gilead Launches Access Program to Provide Anti-HIV Therapy Viread in 68 Developing Countries at No Profit
Printer Friendly Version 
March 11, 2003 - 8:33 a.m.
Gilead Sciences' Hepatitis B Drug Hepsera Approved for Marketing in European Union
Printer Friendly Version 
February 27, 2003 - 8:36 a.m.
Results of Two Pivotal Studies of Gilead's Hepsera Published in the New England Journal of Medicine
Printer Friendly Version 
February 21, 2003 - 8:01 a.m.
European CPMP Gives Positive Opinion to Extend the Indication of Viread, Gilead's Once-Daily Treatment for HIV Infection
Printer Friendly Version 
February 11, 2003 - 8:13 a.m.
Phase III Data Show Emtricitabine Maintains Viral Load Suppression as Part of Once-Daily, Protease-Sparing Anti-HIV Regimen
Printer Friendly Version 
February 11, 2003 - 8:11 a.m.
96-Week Data From Phase III Study Show Long-Term Efficacy With Reduced Risk of Lipid and Metabolic Changes for Viread Versus Stavudine in Treatment-Naive HIV Patients
Printer Friendly Version 
January 30, 2003 - 4:12 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2002 Financial Results; Full Year Product Sales of $424 Million, Up 122 Percent over 2001; Net Income of $72 Million for 2002
Printer Friendly Version 
January 24, 2003 - 2:52 a.m.
Gilead Sciences to Release Fourth Quarter and Year-End 2002 Financial Results on Thursday, January 30, 2003; Conference Call and Webcast to Follow
Printer Friendly Version 
January 23, 2003 - 4:41 p.m.
Gilead Sciences Completes Acquisition of Triangle Pharmaceuticals
Printer Friendly Version 
January 16, 2003 - 8:36 a.m.
Gilead Sciences Successfully Completes Tender Offer for Shares of Triangle Pharmaceuticals with 97 Percent of Shares Tendered
Printer Friendly Version 
NASDAQ (US Dollar)
$81.21
 Stock is Down 0.38 (0.47%)
Data as of 10/20/17 4:15 p.m. ET
Minimum 20 minute delay
Refresh Quote